Purespring Therapeutics
Cambridge, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $175M
Overview
A gene therapy biotech targeting podocytes to treat genetic and chronic kidney diseases.
Rare DiseaseNephrology
Technology Platform
A proprietary AAV-based gene therapy platform engineered to selectively target and deliver genetic payloads to podocytes, the crucial filtering cells in the kidney.
Funding History
1Total raised:$175M
PIPE$175M
Opportunities
To establish a new treatment paradigm in nephrology, a field dominated by symptomatic management rather than cures.
Risk Factors
Unproven delivery and long-term expression of gene therapy in the kidney, and potential immune responses to AAV vectors.
Competitive Landscape
A first-mover in direct kidney podocyte gene therapy, competing with broader nephrology biotechs and large pharma exploring RNAi and small molecules.